Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
NCT ID: NCT00000318
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
202 participants
INTERVENTIONAL
1994-12-31
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2
NCT00000319
Buprenorphine Maintenance for Opioid Addicts - 3
NCT00000204
Buprenorphine Maintenance for Opioid Addicts - 2
NCT00000203
Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1
NCT00000216
Buprenorphine Maintenance for Opioid Addicts - 1
NCT00000202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Maintenance treatment with daily medication
Buprenorphine
1. Experimental Maintenance treatment with daily medication
2. Experimental Maintenance treatment with thrice-weekly medication
2
Maintenance treatment with thrice-weekly medication
Buprenorphine
1. Experimental Maintenance treatment with daily medication
2. Experimental Maintenance treatment with thrice-weekly medication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Buprenorphine
1. Experimental Maintenance treatment with daily medication
2. Experimental Maintenance treatment with thrice-weekly medication
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
21 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yale University School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard Schottenfeld, M.D.
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
APT Residential Services Division
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R01-09803-1
Identifier Type: -
Identifier Source: secondary_id
NIDA-09803-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.